Tenderwize
Wróć do wyszukiwania

Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 307 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform PEN (ATC-Code nach WHO: L03AX13)

20/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

20 / 100

Złożoność

30 / 100

Czynniki ryzyka

The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...

AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Glatiramer acetate in PEN dosage form (ATC L03AX13) to patients insured by AOK PLUS in Saxony and Thuringia
  • Non-exclusive rebate agreement; no guaranteed purchase volumes or exclusivity
Pokaż pełne podsumowanie

Non-exclusive pharmaceutical rebate agreement (Rabattvereinbarung) under §130a Abs.8 SGB V via an open-house model for Glatiramer acetate in PEN dosage form (ATC L03AX13), managed by AOK PLUS for Saxony and Thuringia. Open to all qualified pharmaceutical entrepreneurs; no exclusivity, no guaranteed volumes, and no traditional award criteria. The contract ends 30.06.2027. First submission deadline: 02.06.2025; further rolling deadlines available. Detailed terms and discount amounts are confidential and available only after access to the DTVP project room. This publication is for transparency only and not a formal procurement procedure.

Ryzyka

The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...

AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG with respect to the offered medicinal products
  • Must accept the fixed terms of the rebate agreement; no individual negotiations

Eligibility

  • Must submit a declaration of no grounds for exclusion (§§123,124 GWB) and a declaration regarding Russia sanctions (EU Reg. 833/2014)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria applied; participation is open to all qualified entrepreneurs who accept the terms.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN

Non-exclusive rebate agreement for the supply of Glatiramer acetate in PEN formulation to AOK PLUS for patients in Saxony and Thuringia. Open-house model; no minimum volume guaranteed; no exclusivity; contract ends 30.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria applied; participation is open to all qualified entrepreneurs who accept the terms.

Termin

Expired Jun 02, 2025

Szczegóły zamówienia

Data publikacji
17 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
255277-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3